Literature DB >> 26995266

Sepsis: in search of cure.

Chikkamenahalli Lakshminarayana Lakshmikanth1, Shancy Petsel Jacob1, Vyala Hanumanthareddy Chaithra1, Hugo Caire de Castro-Faria-Neto2, Gopal Kedihithlu Marathe3.   

Abstract

INTRODUCTION: Sepsis is a complex inflammatory disorder believed to originate from an infection by any types of microbes and/or their products. It is the leading cause of death in intensive care units (ICUs) throughout the globe. The mortality rates depend both on the severity of infection and the host's response to infection.
METHODS: Literature survey on pathobiology of sepsis in general and failure of more than hundred clinical trials conducted so far in search of a possible cure for sepsis resulted in the preparation of this manuscript.
FINDINGS: Sepsis lacks a suitable animal model that mimics human sepsis. However, based on the results obtained in animal models of sepsis, clinical trials conducted so far have been disappointing. Although involvement of multiple mediators and pathways in sepsis has been recognized, only few components are being targeted and this could be the major reason behind the failure of clinical trials.
CONCLUSION: Inability to recognize a single critical mediator of sepsis may be the underlying cause for the poor therapeutic intervention of sepsis. Therefore, sepsis is still considered as a disease-in search of cure.

Entities:  

Keywords:  Activated protein C; Cytokines; Lipopolysaccharide (LPS); Sepsis; Toll-like receptors

Mesh:

Substances:

Year:  2016        PMID: 26995266     DOI: 10.1007/s00011-016-0937-y

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  195 in total

1.  Immunomodulatory drugs regulate HMGB1 release from activated human monocytes.

Authors:  Hanna Schierbeck; Heidi Wähämaa; Ulf Andersson; Helena Erlandsson Harris
Journal:  Mol Med       Date:  2010-04-09       Impact factor: 6.354

2.  Circulating presepsin (soluble CD14 subtype) as a marker of host response in patients with severe sepsis or septic shock: data from the multicenter, randomized ALBIOS trial.

Authors:  Serge Masson; Pietro Caironi; Caterina Fanizza; Ralf Thomae; Roberto Bernasconi; Andrea Noto; Roberto Oggioni; Giovanni Stefano Pasetti; Marilena Romero; Gianni Tognoni; Roberto Latini; Luciano Gattinoni
Journal:  Intensive Care Med       Date:  2014-10-16       Impact factor: 17.440

3.  Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group.

Authors:  S M Opal; C J Fisher; J F Dhainaut; J L Vincent; R Brase; S F Lowry; J C Sadoff; G J Slotman; H Levy; R A Balk; M P Shelly; J P Pribble; J F LaBrecque; J Lookabaugh; H Donovan; H Dubin; R Baughman; J Norman; E DeMaria; K Matzel; E Abraham; M Seneff
Journal:  Crit Care Med       Date:  1997-07       Impact factor: 7.598

4.  Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group.

Authors:  R V McCloskey; R C Straube; C Sanders; S M Smith; C R Smith
Journal:  Ann Intern Med       Date:  1994-07-01       Impact factor: 25.391

Review 5.  Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock.

Authors:  Edwin S Van Amersfoort; Theo J C Van Berkel; Johan Kuiper
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

6.  Multicenter, randomized, placebo-controlled phase III study of pyridoxalated hemoglobin polyoxyethylene in distributive shock (PHOENIX).

Authors:  Jean-Louis Vincent; Christopher T Privalle; Mervyn Singer; José A Lorente; Erwin Boehm; Andreas Meier-Hellmann; Harald Darius; Ricard Ferrer; Josep-Maria Sirvent; Gernot Marx; Joseph DeAngelo
Journal:  Crit Care Med       Date:  2015-01       Impact factor: 7.598

7.  Extracellular histone H3 levels are inversely correlated with antithrombin levels and platelet counts and are associated with mortality in sepsis patients.

Authors:  Karin C A A Wildhagen; Maryse A Wiewel; Marcus J Schultz; Janneke Horn; Roy Schrijver; Chris P M Reutelingsperger; Tom van der Poll; Gerry A F Nicolaes
Journal:  Thromb Res       Date:  2015-07-23       Impact factor: 3.944

8.  The Prognostic Value of suPAR Compared to Other Inflammatory Markers in Patients with Severe Sepsis.

Authors:  Anna Gustafsson; Lennart Ljunggren; Mikael Bodelsson; Ingrid Berkestedt
Journal:  Biomark Insights       Date:  2012-04-10

9.  Adenosine-5'-triphosphate (ATP) protects mice against bacterial infection by activation of the NLRP3 inflammasome.

Authors:  Yang Xiang; Xuan Wang; Chao Yan; Qian Gao; Sheng-An Li; Jie Liu; Kaifeng Zhou; Xiaolong Guo; Wenhui Lee; Yun Zhang
Journal:  PLoS One       Date:  2013-05-22       Impact factor: 3.240

Review 10.  Antimicrobial Peptides in Human Sepsis.

Authors:  Lukas Martin; Anne van Meegern; Sabine Doemming; Tobias Schuerholz
Journal:  Front Immunol       Date:  2015-08-20       Impact factor: 7.561

View more
  20 in total

1.  IL-33 attenuates mortality by promoting IFN-γ production in sepsis.

Authors:  Qi Bao; Ran Lv; Min Lei
Journal:  Inflamm Res       Date:  2018-04-02       Impact factor: 4.575

2.  Coupling killing to neutralization: combined therapy with ceftriaxone/Pep19-2.5 counteracts sepsis in rabbits.

Authors:  Sergio Bárcena-Varela; Guillermo Martínez-de-Tejada; Lukas Martin; Tobias Schuerholz; Ana Gloria Gil-Royo; Satoshi Fukuoka; Torsten Goldmann; Daniel Droemann; Wilmar Correa; Thomas Gutsmann; Klaus Brandenburg; Lena Heinbockel
Journal:  Exp Mol Med       Date:  2017-06-16       Impact factor: 8.718

3.  A fragment of the alarmin prothymosin α as a novel biomarker in murine models of bacteria-induced sepsis.

Authors:  Pinelopi Samara; Vivi Miriagou; Michael Zachariadis; Olga Mavrofrydi; Vasilis J Promponas; Skarlatos G Dedos; Panagiota Papazafiri; Hubert Kalbacher; Wolfgang Voelter; Ourania Tsitsilonis
Journal:  Oncotarget       Date:  2017-07-25

Review 4.  Emerging Roles of IL-33/ST2 Axis in Renal Diseases.

Authors:  Wei-Yu Chen; Lung-Chih Li; Jenq-Lin Yang
Journal:  Int J Mol Sci       Date:  2017-04-07       Impact factor: 5.923

5.  Delivering Prolonged Intensive Care to a Non-human Primate: A High Fidelity Animal Model of Critical Illness.

Authors:  P Guillaume Poliquin; Mia Biondi; Charlene Ranadheera; Mable Hagan; Alexander Bello; Trina Racine; Mark Allan; Duane Funk; Gregory Hansen; B J Hancock; Murray Kesselman; Todd Mortimer; Anand Kumar; Shane Jones; Anders Leung; Allen Grolla; Kaylie N Tran; Kevin Tierney; Xiangguo Qiu; Darwyn Kobasa; James E Strong
Journal:  Sci Rep       Date:  2017-04-26       Impact factor: 4.379

6.  Therapeutic effect of Schistosoma japonicum cystatin on bacterial sepsis in mice.

Authors:  Huihui Li; Shushu Wang; Bin Zhan; Wenxin He; Liang Chu; Dapeng Qiu; Nan Li; Yongkun Wan; Hui Zhang; Xingzhi Chen; Qiang Fang; Jilong Shen; Xiaodi Yang
Journal:  Parasit Vectors       Date:  2017-05-08       Impact factor: 3.876

Review 7.  Role of the IL-33-ST2 axis in sepsis.

Authors:  Hui Xu; Heth R Turnquist; Rosemary Hoffman; Timothy R Billiar
Journal:  Mil Med Res       Date:  2017-02-02

8.  Ablation of the Right Cardiac Vagus Nerve Reduces Acetylcholine Content without Changing the Inflammatory Response during Endotoxemia.

Authors:  Konstanze Plaschke; Thuc Quyen Monica Do; Florian Uhle; Thorsten Brenner; Markus A Weigand; Jürgen Kopitz
Journal:  Int J Mol Sci       Date:  2018-02-01       Impact factor: 5.923

9.  Escherichia coli Braun Lipoprotein (BLP) exhibits endotoxemia - like pathology in Swiss albino mice.

Authors:  Chikkamenahalli Lakshminarayana Lakshmikanth; Shancy Petsel Jacob; Avinash Kundadka Kudva; Calivarathan Latchoumycandane; Puttaraju Srikanta Murthy Yashaswini; Mosale Seetharam Sumanth; Cassiano F Goncalves-de-Albuquerque; Adriana R Silva; Sridevi Annapurna Singh; Hugo C Castro-Faria-Neto; Sandeep Kumble Prabhu; Thomas M McIntyre; Gopal Kedihithlu Marathe
Journal:  Sci Rep       Date:  2016-10-04       Impact factor: 4.379

Review 10.  TLR4 Signaling Pathway Modulators as Potential Therapeutics in Inflammation and Sepsis.

Authors:  Nikolay N Kuzmich; Konstantin V Sivak; Vladimir N Chubarev; Yuri B Porozov; Tatiana N Savateeva-Lyubimova; Francesco Peri
Journal:  Vaccines (Basel)       Date:  2017-10-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.